Zhu et al. (2022) described ABZ as an anti-PD1 therapy that decreased tumor PDL1 expression through the induction of ubiquitin-mediated PD-L1 protein degradation, making ABZ a promising antitumor therapy candidate. Here, RPL17 is linked to neoplasm.